[go: up one dir, main page]

NO944966L - Multimere former av humant rhinovirusreseptorprotein - Google Patents

Multimere former av humant rhinovirusreseptorprotein

Info

Publication number
NO944966L
NO944966L NO944966A NO944966A NO944966L NO 944966 L NO944966 L NO 944966L NO 944966 A NO944966 A NO 944966A NO 944966 A NO944966 A NO 944966A NO 944966 L NO944966 L NO 944966L
Authority
NO
Norway
Prior art keywords
human
human rhinovirus
hrv
receptor protein
multimeric
Prior art date
Application number
NO944966A
Other languages
English (en)
Other versions
NO944966D0 (no
Inventor
Jeffrey M Greve
Alan Mcclelland
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Publication of NO944966D0 publication Critical patent/NO944966D0/no
Publication of NO944966L publication Critical patent/NO944966L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C07K14/095—Rhinovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nye former og konfigurasjoner av intracellulært addlsjonsmolekyl (ICAM) inkludert multlmere konfigura- sjoner som effektivt blir bundet til humant rhlnovirus og som effektivt kan redusere HRV infiserbarheten. Når de er i en multlmer konfigurasjon, fortrinnsvis som dlmerer, utviser disse proteinene forsterket binding av HRV og kan også redusere HRV inflserbareheten samt infIserbarheten til andre vlruser kjent for å bli bundet til "hoved"-gruppe human rhlnovlrusreseptor (HRR). Multlmerlserte proteiner kan også bil anvendt for å blokkere tlCAM interaksjonen med lymfocytt funksjons-assoslert antigen-1 (LFA-1).
NO944966A 1992-06-22 1994-12-21 Multimere former av humant rhinovirusreseptorprotein NO944966L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90306992A 1992-06-22 1992-06-22
PCT/US1993/005972 WO1994000485A1 (en) 1992-06-22 1993-06-22 Multimeric forms of human rhinovirus receptor protein

Publications (2)

Publication Number Publication Date
NO944966D0 NO944966D0 (no) 1994-12-21
NO944966L true NO944966L (no) 1994-12-21

Family

ID=25416893

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944966A NO944966L (no) 1992-06-22 1994-12-21 Multimere former av humant rhinovirusreseptorprotein

Country Status (10)

Country Link
EP (1) EP0604624A4 (no)
JP (1) JPH06510208A (no)
KR (1) KR950702576A (no)
AU (1) AU675441B2 (no)
CA (1) CA2116109A1 (no)
FI (1) FI946006L (no)
HU (1) HUT75827A (no)
NO (1) NO944966L (no)
RU (1) RU94046450A (no)
WO (1) WO1994000485A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
DE68929096T2 (de) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9520641D0 (en) * 1995-10-10 1995-12-13 Medical Res Council Improvements in or relating to protection against intracellular infection
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
BR112014024398B1 (pt) * 2012-03-31 2022-03-08 R-Pharm International, Llc Polipeptídeo que se liga ao rankl humano, composições terapêuticas compreendendo o dito polipeptídeo, ácido nucleico isolado, vetor de expressão e uso terapêutico do dito polipeptídeo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE125708T1 (de) * 1988-09-28 1995-08-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
ATE79270T1 (de) * 1989-03-09 1992-08-15 Boehringer Ingelheim Pharma Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.
DK0468257T3 (da) * 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein

Also Published As

Publication number Publication date
FI946006A7 (fi) 1994-12-21
EP0604624A4 (en) 1997-03-12
JPH06510208A (ja) 1994-11-17
FI946006A0 (fi) 1994-12-21
HU9403720D0 (en) 1995-02-28
RU94046450A (ru) 1996-10-10
HUT75827A (en) 1997-05-28
AU4543293A (en) 1994-01-24
EP0604624A1 (en) 1994-07-06
AU675441B2 (en) 1997-02-06
NO944966D0 (no) 1994-12-21
KR950702576A (ko) 1995-07-29
WO1994000485A1 (en) 1994-01-06
CA2116109A1 (en) 1994-01-06
FI946006L (fi) 1994-12-21

Similar Documents

Publication Publication Date Title
ATE184049T1 (de) Multimere formen des menschlichen rhinovirus- rezeptorproteins
EA199700359A1 (ru) Пептиды и соединения, связывающиеся с тромбопоэтиновым рецептором
DK0888385T3 (da) GDNF receptor og anvendelser deraf
Mandelboim et al. Self and viral peptides can initiate lysis by autologous natural killer cells
AU4027189A (en) A human rhinovirus receptor protein that inhibits virus infectivity
DE59009034D1 (de) Desodorierende kosmetische mittel.
DK174190D0 (da) Klonede gener, som koder for ig-cd4-fusionsproteiner, og deres anvendelse
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE69932511D1 (de) Chimäre rezeptoren
DK0914325T3 (da) Modulatorer af funktionen af FAS receptorer og andre proteiner
DK0975359T3 (da) Anvendelse af forbindelser, der binder en cytoplasmisk dipeptidase til synergistisk virkning af immunreaktionen
EA199800946A1 (ru) Концентрированный препарат антител
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
NO944966L (no) Multimere former av humant rhinovirusreseptorprotein
BR9807486A (pt) Epìtopos pre-m/m do vìrus da dengue, peptìdios, sintéticos, proteìnas quiméricas e uso das mesmas
Ellis et al. Receptor coupling to G proteins: interactions not affected by lithium
EA200000961A1 (ru) Модуляторы функций рецепторов семейства рецепторов tnf/ngf и других белков
Castro et al. Carbon tetrachloride activation in liver microsomes from rats induced with 3-methylcholantrene
Tegos et al. Glycosylated hemoglobin A2 components
Emerson et al. DIFFERENTIAL RADIOLABELLING OF LYMPHOCYTE MEMBRANE ALLOANTIGENS AND IMMUNOGLOBULINS: VARIATION OF H2O2 CONCENTRATION DURING LACTOPEROXIDASE CATALYZED CELL SURFACE RADIO‐IODINATION
BR9807210A (pt) Processo para a preparação de 3,3-dimetilbutiraldeìdo
Doehring et al. An Investigation of Returns to Trading Strategies in the Live Hog Futures Market
RU92016375A (ru) Днк, содержащая iсам-1, и производные усам-1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application